Li Yujia, Duan Yiqi, Chu Qingqing, Lv Hang, Li Jing, Guo Xiangyun, Gao Yanjiao, Liu Min, Tang Wei, Hu Huili, Liu Hong, Sun Jinpeng, Wang Xiaojie, Yi Fan
Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China; State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Department of Cardiology, Qilu Hospital, Shandong University, Jinan, China.
Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
Kidney Int. 2025 Apr;107(4):652-665. doi: 10.1016/j.kint.2024.12.013. Epub 2025 Jan 17.
Although emerging studies highlight the pivotal role of podocyte senescence in the pathogenesis of diabetic kidney disease (DKD) and aging-related kidney diseases, therapeutic strategies for preventing podocyte senescence are still lacking. Here, we identified a previously unrecognized role of GPR124, a novel adhesion G protein-coupled receptor, in maintaining podocyte structure and function by regulation of cellular senescence in DKD. Podocyte GPR124 was significantly reduced in db/db diabetic (a type 2 diabetic mouse model) and streptozocin-induced diabetic mice (a type 1 diabetic model), which was further confirmed in kidney biopsies from patients with DKD. The level of GPR124 in glomeruli was positively correlated with the estimated glomerular filtration rate and negatively correlated with serum creatinine levels. Podocyte-specific deficiency of GPR124 significantly aggravated podocyte injury and proteinuria in the two models of diabetic mice. Moreover, GPR124 regulated podocyte senescence in both diabetic and aged mice. Mechanistically, GPR124 directly bound with vinculin and negatively regulated focal adhesion kinase (FAK) signaling, thereby mediating podocyte senescence and function. Importantly, overexpression of GPR124 or pharmacological inhibition of FAK protected against podocyte senescence and injury under diabetic conditions. Our studies suggest that targeting GPR124 may be an innovative therapeutic strategy for patients with DKD and aging-related kidney diseases.
尽管新兴研究强调了足细胞衰老在糖尿病肾病(DKD)和衰老相关肾脏疾病发病机制中的关键作用,但目前仍缺乏预防足细胞衰老的治疗策略。在此,我们发现了一种新型黏附G蛋白偶联受体GPR124在维持足细胞结构和功能方面此前未被认识到的作用,其通过调节DKD中的细胞衰老来实现这一功能。在db/db糖尿病小鼠(一种2型糖尿病小鼠模型)和链脲佐菌素诱导的糖尿病小鼠(一种1型糖尿病模型)中,足细胞GPR124显著降低,这在DKD患者的肾活检中得到了进一步证实。肾小球中GPR124的水平与估计的肾小球滤过率呈正相关,与血清肌酐水平呈负相关。在两种糖尿病小鼠模型中,足细胞特异性缺失GPR124显著加重了足细胞损伤和蛋白尿。此外,GPR124在糖尿病和衰老小鼠中均调节足细胞衰老。机制上,GPR124直接与纽蛋白结合并负向调节黏着斑激酶(FAK)信号传导,从而介导足细胞衰老和功能。重要的是,GPR124的过表达或FAK的药理学抑制在糖尿病条件下可防止足细胞衰老和损伤。我们的研究表明,靶向GPR124可能是DKD和衰老相关肾脏疾病患者的一种创新治疗策略。